albumin IV (Rx)

Brand and Other Names:Albuminar, Alba, more...Albuked, Albutein, Flexbumin, Kedbumin, Plasbumin, Albuminex
  • Print

Dosing & Uses

AdultPediatric

Dosage Forms & Strengths

injectable solution

  • 50mg/mL (5%)
  • 250mg/mL (25%)

Acute Liver Failure

Indicated for maintenance of cardiovascular function following paracentesis due to cirrhotic ascites

6-8 g IV for every 100 mL of ascitic fluid removed

Adult Respiratory Distress Syndrome

Indicated for adult respiratory distress syndrome (ARDS) in conjunction with diuretics to correct fluid volume overload associated with ARDS

25 g IV over 30 minutes; repeat q8hr PRN

Burns

Indicated after 24 hr post burn if severe albumin depletion in order to favor edema reabsorption

Amount of albumin required to achieve adequate plasma volume and protein content should be determined by direct observation of vital signs or measurement of either plasma oncotic pressure or protein content

Cardiopulmonary Bypass

Indicated for procedures as part of the priming fluids for bypass machine

Required dose can be estimated from the difference between the desired and actual total serum protein concentration multiplied by the estimated plasma volume (~40 mL/kg) times 2 (to account for extravascular deficit, which absorbs about half of the administered dose)

Hypoalbuminemia

Indicated for restoration and maintenance of circulating blood volume deficiency caused by illness or active bleeding; when albumin deficiency results from excessive protein loss, the effect of albumin administration will be temporary unless the underlying disorder is reversed

Hemodialysis

Indicated for patients undergoing long-term hemodialysis or for those who are fluid-overloaded and cannot tolerate substantial volumes of sodium for therapy of shock or hypotension

25 g IV

Hypovolemia

Indicated for restoration and maintenance of circulating blood volume where volume deficiency is demonstrated and colloid use is appropriate

Initial 25 g IV; adjust according to volume requirements

Ovarian Hyperstimulation Syndrome

Indicated as a plasma expander in fluid management of severe forms of ovarian hyperstimulation syndrome (OHSS)

50-100 g IV infused over 4 hr; repeat q4-12hr PRN

Dosage Forms & Strengths

injectable solution

  • 50mg/mL (5%)
  • 250mg/mL (25%)

Hemolytic Disease of the Newborn

25% albumin: 1 g/kg/dose IV administered before or during plasma exchange  

Use 25% concentration with extreme caution in neonates, owing to risk of intraventricular hemorrhage from rapid expansion of intravascular volume

Hypovolemia

5% albumin: 0.5-1 g/kg/dose IV infused over 1 hr; may infuse more rapidly for hypovolemic shock

Ascites with Hypoalbuminemia

25% albumin: 1 g/kg/dose IV infused over 2-3 hr; may repeat q8hr until serum albumin above 2.5 g/dL

Next:

Interactions

Interaction Checker

and albumin IV

No Results

     activity indicator 
    No Interactions Found
    Interactions Found

    Contraindicated

      Serious - Use Alternative

        Significant - Monitor Closely

          Minor

            All Interactions Sort By:
             activity indicator 

            Contraindicated (0)

              Serious - Use Alternative (0)

                Monitor Closely (0)

                  Minor (0)

                    Previous
                    Next:

                    Adverse Effects

                    Frequency Not Defined

                    Flushing

                    Urticaria

                    Fever

                    Chills

                    Nausea

                    Vomiting

                    Tachycardia

                    Hypotension

                    Previous
                    Next:

                    Warnings

                    Contraindications

                    Hypersensitivity to commercially available albumin products; suspected hypersensitivity to perflutren, blood, blood products or albumin

                    Severe anemia, heart failure

                    Cautions

                    Hypersensitivity reactions reported; monitor patient during infusion in facility that can respond to anaphylaxis

                    Caution in conditions where hypervolemia and its consequences or hemodilution could represent a special risk (eg, heart failure, arterial hypertension, esophageal varices, pulmonary edema, hemorrhagic diathesis, severe anemia, renal and postrenal anuria)

                    Do not dilute with sterile water for injection as this may cause hemolysis; use D5W or 0.9% NaCl for dilution

                    When replacing large volumes of albumin, control of coagulation and hematocrit is essential; ensure adequate substitution of other blood constituents (eg, coagulation factors, electrolytes, platelets, erythrocytes)

                    Colloid osmotic effect is ~4 times that of human blood; therefore, when concentrated albumin is administered, ensure adequate hydration of the patient; carefully monitor to guard against circulatory overload by assessing arterial blood pressure and pulse rate, central venous pressure, pulmonary artery occlusion pressure, urine output, electrolyte levels, and hematocrit/hemoglobin

                    Albumin is a blood product; extremely remote risk for transmission of viral diseases and variant Creutzfeldt-Jakob disease (vCJD)

                    Previous
                    Next:

                    Pregnancy & Lactation

                    Pregancy

                    No human or animal data are available to indicate the presence or absence of drug-associated risk

                    Lactation

                    Unknown if excreted in human milk

                    Pregnancy Categories

                    A: Generally acceptable. Controlled studies in pregnant women show no evidence of fetal risk.

                    B: May be acceptable. Either animal studies show no risk but human studies not available or animal studies showed minor risks and human studies done and showed no risk.

                    C: Use with caution if benefits outweigh risks. Animal studies show risk and human studies not available or neither animal nor human studies done.

                    D: Use in LIFE-THREATENING emergencies when no safer drug available. Positive evidence of human fetal risk.

                    X: Do not use in pregnancy. Risks involved outweigh potential benefits. Safer alternatives exist.

                    NA: Information not available.

                    Previous
                    Next:

                    Pharmacology

                    Mechanism of Action

                    Replacement of plasma protein; increases intravascular oncotic pressure, mobilizes fluids from interstitial into intravascular space

                    Distribution

                    Plasma compartment: 30-40%

                    Extravascular compartments: 67%

                    Half-life, distribution: 16 hr; inversely proportional to plasma albumin concentrations

                    Metabolism

                    Minimally in the liver; main site is unknown

                    Elimination

                    Elimination half-life: 15-20 days

                    Excretion: Intestinal mucosa, not via kidney

                    Previous
                    Next:

                    Administration

                    IV Incompatibilities

                    Additive: Verapamil

                    Y-site: Fat emulsions, midazolam, vancomycin, verapamil

                    IV Compatibilities

                    Solution: Dextrose solutions, saline solutions, dextrose-saline, Ringer LR, Na-lactate 1/6M

                    Y-site: Diltiazem, lorazepam

                    IV Preparation

                    Reconstitution: If 5% human albumin is unavailable, dilute 25% human albumin with NS or D5W

                    Do NOT use sterile water as diluent - risk of potentially fatal hemolysis and acute renal failure

                    IV Administration

                    For IV administration only

                    5% solution: Use for hypovolemia or patients who are intravascularly depleted

                    25% solution: Use in patients who have fluid or sodium restrictions, or to mobilize fluids

                    Use within 4 hr after opening vial; discard unused portion

                    Do not dilute 5% solution

                    Albumin 25% may be given undiluted or diluted in in 0.9% NaCl

                    May give in combination or through same administration set as saline or carbohydrates

                    Do not use with ethanol or protein hydrolysates; precipitation may form

                    Storage

                    Store at <30°C (86°F); do not freeze

                    Store vial in outer carton to protect from light

                    Do not use solution if turbid or contains a deposit; use within 4 hr of opening vial; discard unused portion

                    Previous
                    Next:

                    Images

                    BRAND FORM. UNIT PRICE PILL IMAGE
                    Plasbumin 5 % intravenous
                    -
                    5 % vial
                    Plasbumin 5 % intravenous
                    -
                    5 % vial
                    albumin, human 5 % intravenous
                    -
                    5 % solution
                    albumin, human 5 % intravenous
                    -
                    5 % solution
                    Albutein 5 % intravenous
                    -
                    5 % vial
                    Albutein 5 % intravenous
                    -
                    5 % vial
                    AlbuRx (Human) 5 % intravenous
                    -
                    5 % vial
                    AlbuRx (Human) 5 % intravenous
                    -
                    5 % vial

                    Copyright © 2010 First DataBank, Inc.

                    Previous
                    Next:

                    Patient Handout

                    Patient Education
                    albumin, human 5 % intravenous

                    NO MONOGRAPH AVAILABLE AT THIS TIME

                    USES: Consult your pharmacist.

                    HOW TO USE: Consult your pharmacist.

                    SIDE EFFECTS: Consult your pharmacist.In the US -Call your doctor for medical advice about side effects. You may report side effects to FDA at 1-800-FDA-1088 or at www.fda.gov/medwatch.In Canada - Call your doctor for medical advice about side effects. You may report side effects to Health Canada at 1-866-234-2345.

                    PRECAUTIONS: Consult your pharmacist.

                    DRUG INTERACTIONS: Consult your pharmacist.Keep a list of all your medications with you, and share the list with your doctor and pharmacist.

                    OVERDOSE: If someone has overdosed and has serious symptoms such as passing out or trouble breathing, call 911. Otherwise, call a poison control center right away. US residents can call their local poison control center at 1-800-222-1222. Canada residents can call a provincial poison control center.

                    NOTES: No monograph available at this time.

                    MISSED DOSE: Consult your pharmacist.

                    STORAGE: Consult your pharmacist.Do not flush medications down the toilet or pour them into a drain unless instructed to do so. Properly discard this product when it is expired or no longer needed. Consult your pharmacist or local waste disposal company for more details about how to safely discard your product.

                    Information last revised July 2016. Copyright(c) 2021 First Databank, Inc.

                    IMPORTANT: HOW TO USE THIS INFORMATION: This is a summary and does NOT have all possible information about this product. This information does not assure that this product is safe, effective, or appropriate for you. This information is not individual medical advice and does not substitute for the advice of your health care professional. Always ask your health care professional for complete information about this product and your specific health needs.

                    Previous
                    Next:

                    Formulary

                    FormularyPatient Discounts

                    Adding plans allows you to compare formulary status to other drugs in the same class.

                    To view formulary information first create a list of plans. Your list will be saved and can be edited at any time.

                    Adding plans allows you to:

                    • View the formulary and any restrictions for each plan.
                    • Manage and view all your plans together – even plans in different states.
                    • Compare formulary status to other drugs in the same class.
                    • Access your plan list on any device – mobile or desktop.

                    The above information is provided for general informational and educational purposes only. Individual plans may vary and formulary information changes. Contact the applicable plan provider for the most current information.

                    Tier Description
                    1 This drug is available at the lowest co-pay. Most commonly, these are generic drugs.
                    2 This drug is available at a middle level co-pay. Most commonly, these are "preferred" (on formulary) brand drugs.
                    3 This drug is available at a higher level co-pay. Most commonly, these are "non-preferred" brand drugs.
                    4 This drug is available at a higher level co-pay. Most commonly, these are "non-preferred" brand drugs or specialty prescription products.
                    5 This drug is available at a higher level co-pay. Most commonly, these are "non-preferred" brand drugs or specialty prescription products.
                    6 This drug is available at a higher level co-pay. Most commonly, these are "non-preferred" brand drugs or specialty prescription products.
                    NC NOT COVERED – Drugs that are not covered by the plan.
                    Code Definition
                    PA Prior Authorization
                    Drugs that require prior authorization. This restriction requires that specific clinical criteria be met prior to the approval of the prescription.
                    QL Quantity Limits
                    Drugs that have quantity limits associated with each prescription. This restriction typically limits the quantity of the drug that will be covered.
                    ST Step Therapy
                    Drugs that have step therapy associated with each prescription. This restriction typically requires that certain criteria be met prior to approval for the prescription.
                    OR Other Restrictions
                    Drugs that have restrictions other than prior authorization, quantity limits, and step therapy associated with each prescription.
                    Additional Offers
                    Email to Patient

                    From:

                    To:

                    The recipient will receive more details and instructions to access this offer.

                    By clicking send, you acknowledge that you have permission to email the recipient with this information.

                    Email Forms to Patient

                    From:

                    To:

                    The recipient will receive more details and instructions to access this offer.

                    By clicking send, you acknowledge that you have permission to email the recipient with this information.

                    Previous
                    Medscape prescription drug monographs are based on FDA-approved labeling information, unless otherwise noted, combined with additional data derived from primary medical literature.